Fusion Pharmaceuticals racks up $105 mln Series B
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, has raised $105 million in Series B financing. Varian and OrbiMed led the round with participation from other investors that included Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Healthcap, Adams Street Partners, Johnson & Johnson Innovation – JJDC Inc, TPG Biotech, Seroba Life Sciences, Genesys Capital and FACIT. In conjunction with the funding, Deepak Khuntia, senior vice president and chief medical officer at Varian, Chau Q. Khuong, a partner at OrbiMed and Heather Preston, a managing director at Pivotal bioVenture Partners, will join Fusion’s board of directors.
3 April 2019•1 min read
